Evidence map›Paper›PMID 37519105›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2023

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma

Christian Messerli, Gertrud Wiedemann, Naomi Porret, Michael Nagler, Katja Seipel, Barbara Jeker, Urban Novak, Sacha Zeerleder, Ulrike Bacher, Thomas Pabst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christian MesserliUniversity Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland
Gertrud WiedemannUniversity Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland
Naomi PorretUniversity Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland
Michael NaglerUniversity Institute of Clinical Chemistry, University Hospital and University of Bern, Bern, Switzerland
Katja SeipelUniversity of Bern, Department for Biomedical Research, Bern, Switzerland
Barbara JekerUniversity Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland
Urban NovakUniversity Hospital and University of Bern, Department of Medical Oncology, Bern, Switzerland
Sacha ZeerlederUniversity Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland
Ulrike BacherUniversity Hospital and University of Bern, Department of Hematology and Central Hematology Laboratory, Bern, Switzerland
Thomas PabstUniversity Hospital and University of Bern, Department of Medical Oncology, Bern, SwitzerlandORCID 0000-0002-6055-5257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are significant complications in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing chimeric antigen receptor T-cell (CAR-T cell) therapy. However, it remains unclear whether CAR-T cell expression itself is clinically relevant. We assessed CAR-T cell mRNA expression and DNA concentration by digital droplet PCR in peripheral blood from 14 sequential CAR-T cell recipients. Patients were grouped according to CAR-T cell peak expression. Patients with high CAR-T cell peak expression (8 patients; 57%) had higher rates of ICANS (p=0.0308) and intensive care unit admission (p=0.0404), longer durations of hospitalization (p=0.0077), and, although not statistically significant, a higher rate of CRS (p=0.0778). There was a correlation of CAR-T cell mRNA expression with DNA concentration, but CAR-T cell expression levels failed to correlate to response or survival. Our data suggest that higher CAR-T cell peak mRNA expression is associated with increased risk for ICANS and possibly CRS, requiring further investigation in larger studies.

Indexed as

Lymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenHumansImmunotherapy, AdoptiveNeurotoxicity SyndromesRNA, MessengerT-Lymphocytescell-associated neurotoxicityReceptors, Chimeric AntigenRNA, MessengerCAR-T cell expansionCAR-T cell therapyDiffuse large B-cell lymphomaDigital droplet PCRImmune effector cell-associated neurotoxicity syndromeLymphomasMolecular biologyNeoplasiaNon-Hodgkin lymphomaStem cell transplantationTransplant-related toxicity

Identifiers

PMID37519105
PMCPMC10476258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.